VistaGen Therapeutics’ (VTGN) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of VistaGen Therapeutics (NASDAQ:VTGN) in a research report released on Wednesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 18th. Wall Street Zen raised shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, VistaGen Therapeutics presently has an average rating of “Hold”.

VistaGen Therapeutics Stock Down 4.3%

NASDAQ VTGN opened at $4.03 on Wednesday. VistaGen Therapeutics has a 12-month low of $1.90 and a 12-month high of $4.39. The firm’s 50 day moving average is $3.33 and its 200-day moving average is $2.68. The company has a market capitalization of $123.64 million, a PE ratio of -2.26 and a beta of 0.55.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.22 million. As a group, sell-side analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC lifted its holdings in shares of VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after buying an additional 299,304 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of VistaGen Therapeutics by 52.9% during the fourth quarter. Millennium Management LLC now owns 38,732 shares of the company’s stock worth $114,000 after buying an additional 13,395 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics during the second quarter worth $190,000. Marshall Wace LLP acquired a new stake in shares of VistaGen Therapeutics during the second quarter worth $69,000. Finally, Bank of America Corp DE lifted its holdings in shares of VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares in the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.